Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.
Berenson JR, et al. Among authors: niesvizky r.
Cancer. 2005 Nov 15;104(10):2141-8. doi: 10.1002/cncr.21427.
Cancer. 2005.
PMID: 16206291
Free article.
Clinical Trial.